Dolutegravir (TIVICAY)
Integrase strand transfer inhibitor (INSTI) antiretroviral
Dolutegravir (TIVICAY)
Forms and strengths
Form: TabletStrength: 5 mg (dispersible tablet), 10 mg, 25 mg, 50 mg
References
Indication
- Dolutegravir, combined with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults.
- It is also indicated for integrase-inhibitor-naïve pediatric patients aged 4 weeks and older weighing at least 3 kg, in combination with other antiretrovirals.
- Alternative combinations that avoid metabolic-inducing drugs should be used where possible in patients with confirmed or suspected resistance to integrase inhibitors.
Pregnancy
- Dolutegravir should not be used during pregnancy unless the potential benefit outweighs the potential risk to the fetus.
- Large birth-outcome surveillance studies involving tens of thousands of pregnancies have not shown a significant difference in the rate of neural tube defects among infants born to people taking dolutegravir at conception compared with other antiretroviral regimens or with HIV-negative pregnancies.
- An earlier interim analysis from one of these surveillance studies had raised a potential signal for neural tube defects with dolutegravir exposure around conception; later, larger analyses did not confirm a significantly increased risk.
- Dolutegravir readily crosses the placenta, and umbilical cord blood concentrations in newborns are slightly higher than the mother's own blood concentrations.
- Animal reproduction studies did not show teratogenicity or significant fetal harm at doses many times the human exposure.
- Healthcare professionals are encouraged to register pregnant patients exposed to dolutegravir with the Antiretroviral Pregnancy Registry.
Breastfeeding
- Mothers with HIV should not breastfeed their infants, to avoid the risk of passing HIV through breast milk.
- Dolutegravir passes into human breast milk in small amounts.
- Nursing mothers taking dolutegravir should be instructed not to breastfeed.
Geriatrics
- Clinical studies did not include enough patients aged 65 and older to determine whether they respond differently than younger adults.
- Caution should be used when dosing older adults, given the greater likelihood of reduced liver, kidney, or heart function, and of other health conditions or medications.
Pediatrics
- Dolutegravir is approved for integrase-inhibitor-naïve pediatric patients aged 4 weeks and older weighing at least 3 kg, dosed according to body weight.
- It has not been established as safe and effective in infants under 4 weeks of age, infants weighing less than 3 kg, or children with documented or suspected resistance to integrase inhibitors.
- Dispersible tablets are recommended for children weighing less than 20 kg, or for any patient who cannot swallow tablets whole; to reduce choking risk, no more than one tablet should be swallowed at a time.
Dosage & Administration
- The usual adult dose is 50 mg once daily for treatment-naïve or integrase-inhibitor-naïve treatment-experienced patients; patients with confirmed integrase-inhibitor resistance take 50 mg twice daily.
- The dose is increased to 50 mg twice daily when dolutegravir is combined with certain enzyme-inducing drugs, such as efavirenz, rifampin, tipranavir/ritonavir, or fosamprenavir/ritonavir.
- Pediatric dosing is weight-based, ranging from 5 mg once daily in infants weighing 3 to less than 6 kg up to the standard 50 mg adult dose in children weighing 20 kg or more, using either the dispersible or regular tablet.
- Dispersible tablets may be swallowed whole with water or dispersed in water and taken within 30 minutes of dispersing; they must not be chewed, cut, or crushed, and are not interchangeable milligram-for-milligram with regular tablets.
- No dose adjustment is required for mild or moderate liver impairment; dolutegravir is not recommended in severe liver impairment because it has not been studied in this population.
- No dose adjustment is required for mild, moderate, or severe kidney impairment in patients without integrase-inhibitor resistance; caution is needed in resistant patients with severe kidney impairment, since lower drug levels may allow further resistance to develop.
- If a dose is missed, it should be taken as soon as possible unless it is within 4 hours of the next scheduled dose, in which case the missed dose should be skipped; doses should never be doubled.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is limited experience with dolutegravir overdose; doses up to 250 mg in healthy subjects produced no symptoms beyond those seen at recommended doses.
- There is no specific treatment or antidote; management is supportive.
- Dolutegravir is highly bound to plasma proteins, so it is unlikely to be significantly removed by dialysis.
Common side effects
- Insomnia may occur.
- Headache may occur.
- Fatigue may occur.
- Nausea may occur.
- Diarrhea may occur.
- Abnormal or vivid dreams may occur.
- Dizziness may occur.
- Skin rash may occur.
- Vertigo may occur.
- Abdominal pain, abdominal discomfort, gas, or vomiting may occur.
- Joint or muscle pain may occur.
- Weight gain has been reported.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Liver toxicity, including elevated liver enzymes, hepatitis, and acute liver failure, has been reported, even in patients with no pre-existing liver disease.
- Severe hypersensitivity reactions have occurred, marked by rash together with fever, fatigue, muscle or joint aches, blisters, mouth sores, swelling of the face, or liver inflammation; dolutegravir must be stopped immediately if this occurs.
- Immune reconstitution inflammatory syndrome, an inflammatory reaction to hidden infections or autoimmune conditions as the immune system recovers, can occur, sometimes months after starting treatment.
- Worsening of liver enzyme levels can occur in patients with hepatitis B or C co-infection, particularly if anti-hepatitis B treatment is stopped or interrupted.
- Reversible sideroblastic anemia, a blood disorder affecting red blood cell formation, has been reported.
- Acute liver failure has been reported after marketing.
- Suicidal thoughts or suicide attempts have been reported, particularly in patients with a prior history of depression or mental illness.
- Depression has been reported.
- Kidney impairment has been reported.
- Seek urgent medical attention for yellowing of the skin or eyes, a severe rash with fever, or thoughts of self-harm.
Use with caution
- Use with caution in patients with hepatitis B or C co-infection, and monitor liver chemistry closely, especially at the start of therapy.
- Use with caution in patients with any degree of liver impairment; dolutegravir is not recommended in severe liver impairment.
- Exercise caution when driving or operating machinery, since dizziness can occur.
- Use with caution in patients switching between tablet and dispersible tablet formulations, since they are not interchangeable milligram-for-milligram and incorrect dosing can lead to underdosing or greater side effects.
- Use with caution in older adults due to a higher likelihood of reduced organ function or other medical conditions.
- Monitor serum creatinine, as dolutegravir can cause a modest increase by blocking its tubular secretion without truly reducing kidney filtration function.
- Patients on antiretroviral therapy, including dolutegravir, can still develop opportunistic infections and should remain under regular medical observation.
Contraindications
- Contraindicated in patients with known hypersensitivity to dolutegravir or to any ingredient in the formulation.
- Contraindicated in combination with dofetilide, due to the risk of life-threatening dofetilide toxicity.
- Contraindicated in combination with fampridine (also known as dalfampridine), due to an increased risk of seizures.
Drug interactions
- Etravirine reduces dolutegravir levels; the dolutegravir dose must be increased to twice daily unless etravirine is combined with a boosted protease inhibitor.
- Efavirenz and rifampin reduce dolutegravir levels and require an increase to twice-daily dolutegravir dosing.
- Nevirapine co-administration should be avoided due to insufficient data to guide dosing.
- Anticonvulsants including oxcarbazepine, phenytoin, phenobarbital, and carbamazepine reduce dolutegravir levels and require twice-daily dosing.
- Antacids and other products containing polyvalent cations such as magnesium or aluminum, laxatives, sucralfate, and buffered medications significantly reduce dolutegravir absorption; dolutegravir should be taken 2 hours before or 6 hours after these products.
- Calcium and iron supplements, including multivitamins containing them, can be taken at the same time as dolutegravir if taken with food; under fasting conditions, dolutegravir should be taken 2 hours before or 6 hours after these supplements.
- Dolutegravir increases metformin levels, so a metformin dose adjustment may be needed when starting or stopping dolutegravir.
- St. John's Wort can lower dolutegravir levels and should generally be avoided, or the dolutegravir dose increased to twice daily if it is used.
- Atazanavir and atazanavir/ritonavir increase dolutegravir levels, but no dose adjustment is needed.
- Tipranavir/ritonavir and fosamprenavir/ritonavir reduce dolutegravir levels and require twice-daily dosing.
- No clinically relevant interaction was found with midazolam, tenofovir, methadone, rilpivirine, daclatasvir, or hormonal contraceptives containing norgestimate and ethinyl estradiol.
Food interactions
- Dolutegravir tablets and dispersible tablets may be taken with or without food; food increases the amount absorbed but is not required for the medication to work.
Time of administration
- Dolutegravir is usually taken once daily (or twice daily if required by interacting medications) at a consistent time, with or without food; when combined with calcium or iron supplements under fasting conditions, it should be spaced 2 hours before or 6 hours after those supplements.
Storage
- Store TIVICAY 5 mg dispersible tablets and 10 mg tablets in the original container to protect from moisture, with the bottle tightly closed and the desiccant left in place; store below 25°C.
- Store TIVICAY 25 mg and 50 mg tablets below 30°C.
Patient take-away
- Dolutegravir (TIVICAY) is an antiretroviral medication taken with other HIV medicines to control HIV-1 infection.
- It can be taken with or without food, and the dispersible tablet form should not be chewed, cut, or crushed.
- Report any signs of liver problems, such as yellowing skin or eyes, or a severe rash with fever, right away.
- Keep dolutegravir spaced away from antacids, calcium or iron supplements, and certain other medications, as directed by your pharmacist.
- Continue taking dolutegravir exactly as prescribed, even if you feel well, since missing doses can lead to drug resistance.